ONC201 is a medication being studied for its potential to treat a type of brain tumor called Diffuse Intrinsic Pontine Glioma (DIPG) and other similar tumors. It works by targeting specific pathways in cancer cells, which may help to stop the tumor from growing or spreading. This medication is being tested to see if it can improve the time patients live without the disease getting worse.

Everolimus is a medication that is already used to treat some types of cancer. It works by blocking a protein that helps cancer cells grow and divide. In this trial, everolimus is being combined with radiotherapy to see if it can help improve outcomes for patients with newly diagnosed brain tumors, specifically those with certain genetic mutations. The goal is to see if this combination can help patients live longer without their disease progressing.

Diffuse Intrinsic Pontine Glioma (DIPG) – This is a type of brain tumor that occurs in the pons, a part of the brainstem. It primarily affects children and is characterized by its diffuse growth pattern, meaning it spreads widely through the brain tissue. The tumor cells infiltrate the normal brain tissue, making it difficult to remove surgically. As the disease progresses, it can cause symptoms such as difficulty with balance and coordination, problems with eye movements, and facial weakness. Over time, these symptoms can worsen as the tumor grows and affects more areas of the brainstem. DIPG is known for its aggressive nature and rapid progression.

Diffuse Midline Glioma, H3K28M Mutant – This is a type of brain tumor that occurs in the midline structures of the brain, such as the thalamus, brainstem, or spinal cord. It is characterized by a specific genetic mutation known as H3K28M, which affects the histone proteins involved in DNA packaging. This mutation leads to changes in gene expression that promote tumor growth. The tumor tends to grow diffusely, infiltrating surrounding brain tissue, which complicates surgical removal. As the disease progresses, it can cause neurological symptoms depending on its location, such as motor dysfunction, sensory changes, or cognitive impairments. The progression is typically aggressive, with symptoms worsening as the tumor expands.

Diffuse Midline Glioma, EZHIP Positive – This is a type of brain tumor found in the midline regions of the brain, including the thalamus and brainstem. It is characterized by the presence of the EZHIP protein, which is associated with changes in gene expression that drive tumor growth. The tumor grows diffusely, spreading through the brain tissue and making surgical removal challenging. As it progresses, it can lead to symptoms such as headaches, nausea, and neurological deficits depending on its location. The disease tends to progress rapidly, with increasing severity of symptoms as the tumor enlarges. The diffuse nature of the tumor contributes to its aggressive progression.